For example, in the triple-negative form of breast cancer (TNBC), the most aggressive subtype of breast cancer and the most difficult to treat, MYC is amplified in approximately 57% of cases in contrast to only 7–13% in luminal A-type (ER/PR-positive) cancers (a breast cancer subtype with a more favorable outcome) [23,29]. The gene discussed is MYC; the disease is breast carcinoma.